The funding should last three years, but FDA approval is still four to six years out. Three hundred fifty million people are infected with hepatitis worldwide. It's the ninth leading cause of death globally, but you don't hear much about it in the western world. Novirio Pharmaceuticals develops drugs that inhibit the replication of hepatitis B. Early-stage human trials look promising. The company established a level of safety so high in animal trials that the FDA has cleared its LdT drug for a longer initial testing period in humans, Novirio spokesman David Franklin says.
Early results show the virus count dropping more than a thousandfold with the therapy.
If it's approved, Novirio plans to partner with other drug companies to distribute the treatment in Asia. FDA approval for all three drugs is three to four years out. Develops database software management and data-mining solutions. WhamTech president Mark Armstrong says solutions offered by competitors Oracle and Microsoft cannot perform dual functions without having to add more software. Indeed, multiple platforms must be aggregated for single-tasking, thus costing users more cash than necessary.